In this issue of Insights, we summarize a recent discussion held with a number of pharmaceutical companies on US health policy, potential priorities for the Trump administration, and yes, pricing. Tim Wilsdon, an expert in international policy issues affecting the development and commercialization of medicines, led the discussion.
To read more, click the link below.
2025 MDA Clinical & Scientific Conference Review
The Muscular Dystrophy Association (MDA) Clinical & Scientific Conference 2025 took place in Dallas, bringing together the neuromuscular (NMD) disease...